NCT01551498

Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention)

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Potential Effects of the Dietary Supplement Anatabloc on Antithyroid Autoantibodies and Thyroid Function in Autoimmune Thyroiditis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 165 (actual)
• Sponsor: Rock Creek Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a study to evaluate the safety, tolerability, and potential effects of Anatabloc dietary supplementation on antithyroid autoantibodies, thyroid structure, and thyroid function in subjects with autoimmune thyroiditis.

Detailed description

This is a 5-visit, 12-week, double-blind, randomized, placebo-controlled, parallel-group study.

Conditions

• Thyroiditis, Autoimmune

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Anatabloc Supplement	Product, as mint-flavored lozenges (3 mg anatabine per lozenge), to be taken 3 times each day
DIETARY_SUPPLEMENT	Placebo	Placebo, as mint flavored lozenges, to be taken 3 times each day

Timeline

• Start date: 2012-03-01
• Primary completion: 2013-01-01
• Completion: 2013-02-01
• First posted: 2012-03-12
• Last updated: 2015-11-02

Locations

9 sites across 1 country: United States